7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Seagen has announced an update to the label for its antibody-drug conjugate Adcetris (brentuximab vedotin), adding results from the Phase III ECHELON-1 trial. 15 June 2023
The recent rally in Eli Lilly’s market value, which made it to become the most valuable pharmaceutical company in the world, with a market cap of $420 billion, surpassing Johnson & Johnson, has come as the result of its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completing its second final-stage trial for obesity. 15 June 2023
US biotech major Gilead Sciences’ Kite unit today announced that its CAR T-cell therapy helped patients with relapsed or refractory large B-cell lymphoma (LBCL) live longer than historic treatment. 15 June 2023
Federal lawmakers in the USA are pushing for a bill that would limit the structure of how pharmacy benefit managers (PMBs) — companies that operate in between insurers, pharmacists and drugmakers — are paid, although a PBM trade group took issue with the proposed legislation, according to Life Sciences Law360. 15 June 2023
The Commercial Court in Lyon, France, has rejected the request of investment fund Akkadian Partners to postpone the vote on the merger of Erytech with Pherecydes Pharma. 15 June 2023
An investment bank for the UK government has highlighted what it sees as the success of the UK life science sector in raising venture capital in recent years. 15 June 2023
US pharma giant Merck & Co has won out in a lawsuit relating to Bridion (sugammadex), a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anesthesia. 14 June 2023
UK-based ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, has acquired the scientific assets of Imagen Therapeutics from its appointed liquidators. 14 June 2023
Privately-held Californian firm Alladapt Immunotherapeutics has announced top-line results from the Phase I/II Harmony study of its multi-targeted allergy treatment ADP101. 14 June 2023
Japanese drugmaker Chugai Pharmaceutical said today it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for the anti-C5 antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 14 June 2023
Israel-based NeuroSense Therapeutics announced in a Securities and Exchange Commission that it has entered into a collaborative evaluation agreement with a unit of US biotech major Biogen. 14 June 2023
As a functional, practical and intelligent way to regulate medical products in today’s globalized world—especially with increasing public health needs, limited resources and demand for faster and better treatments—the use of regulatory decisions from other jurisdictions represents a powerful and effective alternative. 14 June 2023
The Russian government plans to significantly increase public procurement of drugs against diabetes this year despite the existing shortage of funds, reports The Pharma Letter’s local correspondent. 14 June 2023
The UK subsidiary of Hungarian drugmaker Gedeon Richter today announced that full marketing and distribution rights to an oral contraceptive range of branded generics, acquired from Ireland-headquartered Consilient Health, have been transferred to the company. 14 June 2023
India is to join an international system - the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S) - that fosters cooperation between countries and regulatory authorities on good manufacturing practices (GMPs) in order to improve the quality of its medical products. 14 June 2023
Just months after France’s Ipsen bought liver disease specialist Albireo (Nasdaq: ALBO), the company’s main product Bylvay (odevixibat) has won a new US nod. 14 June 2023
Spanish dermatology-focused drugmaker Almirall has launched a non pre-emptive share capital increase for a total aggregate amount (including nominal value and share issue premium) of around 200 million euros, by issuing more than 24 million new ordinary shares at 8.20 euros. 14 June 2023
French drugmaker Sanofi has placed a strong emphasis on the adoption of artificial intelligence capabilities to facilitate its internal operations. 13 June 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024